Concentrations of
apolipoprotein A-I (
ApoA-I) decrease during
inflammation, which may lead to dysfunctional
ApoA-I-poor
high-density lipoprotein (HDL) particles, and as such, elevate cardiovascular risk. Therefore, rescuing
ApoA-I concentrations, especially during
inflammation, seems beneficial. Recently,
short-chain fatty acids (SCFAs) have received more attention as a strategy in reversing
atherosclerosis. We here evaluated the effects of SCFAs on inflammatory pathways in relation to
ApoA-I transcription. SCFAs dose-response studies were performed in the presence and absence of inflammatory
cytokines.
ApoA-I and
interleukin 8 (IL-8)
mRNA expression were analyzed using qPCR and ELISA, respectively. To study underlying mechanisms,
nuclear factor kappa B (NF-κB) transactivation and changes in
mRNA expressions of the genes targets of bromodomain and extra-terminal (BET) inhibition,
peroxisome proliferator-activated receptor-alpha (PPARα) transactivation and
activator protein 1 (AP-1) pathway were analyzed. SCFAs (except
hexanoic acid) increased
ApoA-I mRNA transcription in both normal and inflammatory conditions and lowered
IL-8 mRNA expression. This anti-inflammatory effect of SCFAs was confirmed by inhibition of NF-κB transactivation. Moreover,
butyric acid increased
carnitine palmitoyltransferase 1 (CPT1), PPARα target gene,
mRNA transcription in both conditions, and there was a negative correlation between CPT1 and NF-κB. Therefore, PPARα transactivation is probably involved in the anti-inflammatory effects of SCFAs, which rescues
ApoA-I transcription. In conclusion,
propionate,
butyrate and
valerate elicit anti-inflammatory effects which might rescue
ApoA-I transcription in inflammatory conditions via PPARα transactivation mediated NF-κB inhibition.